SYRS Stock Overview
A biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Syros Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.95 |
| 52 Week High | US$8.17 |
| 52 Week Low | US$1.43 |
| Beta | 1.58 |
| 11 Month Change | 20.74% |
| 3 Month Change | -67.50% |
| 1 Year Change | -50.38% |
| 33 Year Change | -96.16% |
| 5 Year Change | -98.26% |
| Change since IPO | -98.93% |
Recent News & Updates
Recent updates
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Jul 02Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Syros Pharmaceuticals Is A Buy As New Trials Start
Nov 20Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 08
Shareholder Returns
| SYRS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.7% | 5.6% | 4.2% |
| 1Y | -50.4% | 19.5% | 24.4% |
Return vs Industry: SYRS underperformed the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: SYRS underperformed the US Market which returned 22% over the past year.
Price Volatility
| SYRS volatility | |
|---|---|
| SYRS Average Weekly Movement | 21.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SYRS's share price has been volatile over the past 3 months.
Volatility Over Time: SYRS's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 68 | Conley Chee | www.syros.com |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. Fundamentals Summary
| SYRS fundamental statistics | |
|---|---|
| Market cap | US$42.09m |
| Earnings (TTM) | -US$131.56m |
| Revenue (TTM) | US$4.15m |
12.6x
P/S Ratio-0.4x
P/E RatioIs SYRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYRS income statement (TTM) | |
|---|---|
| Revenue | US$4.15m |
| Cost of Revenue | US$96.39m |
| Gross Profit | -US$92.24m |
| Other Expenses | US$39.32m |
| Earnings | -US$131.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.91 |
| Gross Margin | -2,223.26% |
| Net Profit Margin | -3,170.93% |
| Debt/Equity Ratio | -644.4% |
How did SYRS perform over the long term?
See historical performance and comparison